Hemodynamic characteristics, myocardial kinetics and microvascular rheology of FS-069, a second-generation echocardiographic contrast agent capable of producing myocardial opacification from a venous injection

Cardiovascular Division, University of Virginia, Charlottesville 22908, USA.

OBJECTIVES: We sought to 1) study the effects of FS-069 on cardiac and systemic hemodynamic function, myocardial blood flow, left ventricular wall thickening and pulmonary gas exchange when injected intravenously; and 2) compare the myocardial kinetics and microvascular rheology of FS-069 and Albunex when injected directly into a coronary artery. BACKGROUND: FS-069 is a second-generation echocardiographic contrast agent composed of perfluoropropane-filled albumin microspheres; it is capable of consistent and reproducible myocardial opacification from a venous injection. METHODS: Nine dogs were used to study the effects of FS-069 on hemodynamic function, pulmonary gas exchange, left ventricular wall thickening and myocardial blood flow and to characterize its myocardial kinetics when injected intravenously. These dogs were also used to compare the myocardial kinetics of FS-069 with those of Albunex during intracoronary injections. Nine Sprague-Dawley rats were used to compare the microvascular rheology of these two contrast agents, and in vitro modeling was performed to assess whether the microvascular findings of FS-069 can explain its echocardiographic behavior during direct coronary injections. RESULTS: There were no effects of 30 rapid venous injections of FS-069 (every 20 s) on cardiac output; mean aortic, pulmonary or left atrial pressures; and peak positive and negative first derivative of left ventricular pressure (dP/dt). Similarly, there were no effects of this agent on radiolabeled microsphere-measured regional myocardial blood flow, left ventricular wall thickening or pulmonary gas exchange. When injected intravenously, the myocardial transit of this agent resembled a gamma-variate form. When diluted FS-069 was injected directly into the coronary artery; however, its transit resembled the integral of gamma-variate function, with persistent myocardial opacification lasting several minutes, which was different from that of Albunex. Intravital microscopy revealed that, unlike Albunex, when no bubbles are entrapped within the microcirculation after an arterial injection, a very small fraction of the diluted, larger FS-069 microbubbles are entrapped. In vitro modeling confirmed that this small fraction of microbubbles can result in persistent myocardial opacification. CONCLUSIONS: FS-069 produces no changes in hemodynamic function, myocardial blood flow, left ventricular wall thickening or pulmonary gas exchange when injected intravenously in large amounts. When diluted FS-069 is injected into the coronary artery, a very small fraction of the larger bubbles are entrapped within the microcirculation, resulting in a persistent contrast effect. Thus, although FS-069 is a safe intravenous echocardiographic contrast agent, it cannot provide information on myocardial blood flow when injected directly into a coronary artery.

This article has been cited by other articles:

				K. Kalantarinia, J. T. Belcik, J. T. Patrie, and K. Wei Real-time measurement of renal blood flow in healthy subjects using contrast-enhanced ultrasound Am J Physiol Renal Physiol, October 1, 2009; 297(4): F1129 - F1134. [Abstract] [Full Text] [PDF]

				M. S. Dolan, S. S. Gala, S. Dodla, S. S. Abdelmoneim, F. Xie, D. Cloutier, M. Bierig, S. L. Mulvagh, T. R. Porter, and A. J. Labovitz Safety and Efficacy of Commercially Available Ultrasound Contrast Agents for Rest and Stress Echocardiography: A Multicenter Experience J. Am. Coll. Cardiol., January 6, 2009; 53(1): 32 - 38. [Abstract] [Full Text] [PDF]

				T. H Marwick How dangerous is echocardiographic contrast? Heart, December 1, 2008; 94(12): 1522 - 1523. [Full Text] [PDF]

				S. Kaul Myocardial Contrast Echocardiography: A 25-Year Retrospective Circulation, July 15, 2008; 118(3): 291 - 308. [Full Text] [PDF]

				M. L. Main, J. H. Goldman, and P. A. Grayburn Thinking Outside the "Box" The Ultrasound Contrast Controversy J. Am. Coll. Cardiol., December 18, 2007; 50(25): 2434 - 2437. [Abstract] [Full Text] [PDF]

				M. Braide, H. Rasmussen, A. Albrektsson, and U. Bagge Microvascular behavior and effects of sonazoid microbubbles in the cremaster muscle of rats after local administration. J. Ultrasound Med., July 1, 2006; 25(7): 883 - 890. [Abstract] [Full Text] [PDF]

				P. A. Grayburn Stress Echo Without the Stress: Detection of Coronary Stenosis at Rest by Myocardial Contrast Echocardiography Circulation, August 23, 2005; 112(8): 1085 - 1087. [Full Text] [PDF]

				R. Bekeredjian, P. A. Grayburn, and R. V. Shohet Use of ultrasound contrast agents for gene or drug delivery in cardiovascular medicine J. Am. Coll. Cardiol., February 1, 2005; 45(3): 329 - 335. [Abstract] [Full Text] [PDF]

				X. Yang Imaging of Vascular Gene Therapy Radiology, July 1, 2003; 228(1): 36 - 49. [Abstract] [Full Text] [PDF]

				M. L. Main, A. Magalski, B. A. Morris, M. M. Coen, D. G. Skolnick, and T. H. Good Combined assessment of microvascular integrity and contractile reserve improves differentiation of stunning and necrosis after acute anterior wall myocardial infarction J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1079 - 1084. [Abstract] [Full Text] [PDF]

				N. G. Fisher, J. P. Christiansen, H. Leong-Poi, A. R. Jayaweera, J. R. Lindner, and S. Kaul Myocardial and microcirculatory kinetics of BR14, a novel third-generation intravenous ultrasound contrast agent J. Am. Coll. Cardiol., February 6, 2002; 39(3): 530 - 537. [Abstract] [Full Text] [PDF]

				E. Leistad, K. Ohmori, T. A. Peterson, G. Christensen, and A. N. DeMaria Quantitative assessment of myocardial perfusion during graded coronary artery stenoses by intravenous myocardial contrast echocardiography J. Am. Coll. Cardiol., February 1, 2001; 37(2): 624 - 631. [Abstract] [Full Text] [PDF]

				S. K. Heinle, J. Noblin, P. Goree-Best, A. Mello, G. Ravad, S. Mull, P. Mammen, and P. A. Grayburn Assessment of Myocardial Perfusion by Harmonic Power Doppler Imaging at Rest and During Adenosine Stress : Comparison With 99mTc-Sestamibi SPECT Imaging Circulation, July 4, 2000; 102(1): 55 - 60. [Abstract] [Full Text] [PDF]

				G. Seidel, C. Algermissen, A. Christoph, L. Claassen, M. Vidal-Langwasser, and T. Katzer Harmonic Imaging of the Human Brain : Visualization of Brain Perfusion With Ultrasound Stroke, January 1, 2000; 31(1): 151 - 154. [Abstract] [Full Text] [PDF]

				Y Myreng, P Molstad, K Ytre-Arne, M Aas, L Stoksflod, J O Nossen, and B Oftedal Safety of the transpulmonary ultrasound contrast agent NC100100: a clinical and haemodynamic evaluation in patients with suspected or proved coronary artery disease Heart, September 1, 1999; 82(3): 333 - 335. [Abstract] [Full Text] [PDF]

				J Hancock, H Dittrich, D E Jewitt, and M J Monaghan Evaluation of myocardial, hepatic, and renal perfusion in a variety of clinical conditions using an intravenous ultrasound contrast agent (Optison) and second harmonic imaging Heart, June 1, 1999; 81(6): 636 - 641. [Abstract] [Full Text]

				K. C. Wu, R. J. Kim, D. A. Bluemke, C. E. Rochitte, E. A. Zerhouni, L. C. Becker, and J. A. C. Lima Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1756 - 1764. [Abstract] [Full Text] [PDF]

				A. Z. Linka, D. M. Skyba, R. J. Price, K. Wei, T. C. Skalak, and S. Kaul Spontaneous redistribution after reperfusion: A unique property of AIP 201, an ultrasound contrast agent J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1765 - 1772. [Abstract] [Full Text] [PDF]

				J. L. Cohen, J. Cheirif, D. S. Segar, L. D. Gillam, J. S. Gottdiener, E. Hausnerova, and D. E. Bruns Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent: Results of a phase III multicenter trial J. Am. Coll. Cardiol., September 1, 1998; 32(3): 746 - 752. [Abstract] [Full Text] [PDF]

				D. M. Skyba, R. J. Price, A. Z. Linka, T. C. Skalak, and S. Kaul Direct In Vivo Visualization of Intravascular Destruction of Microbubbles by Ultrasound and its Local Effects on Tissue Circulation, July 28, 1998; 98(4): 290 - 293. [Abstract] [Full Text] [PDF]

				S. Kaul Myocardial Contrast Echocardiography : 15 Years of Research and Development Circulation, November 18, 1997; 96(10): 3745 - 3760. [Full Text]

				J. S. Lee, J. Karch, A. R. Jayaweera, J. R. Lindner, L. P. Lee, D. M. Skyba, and S. Kaul Modeling the myocardial dilution curve of a pure intravascular indicator Am J Physiol Heart Circ Physiol, October 1, 1997; 273(4): H2062 - H2071. [Abstract] [Full Text] [PDF]

				M. S. Bayfield, J. R. Lindner, S. Kaul, S. Ismail, M. L. K. Sheil, N. C. Goodman, R. Zacour, and W. D. Spotnitz DEOXYGENATED BLOOD MINIMIZES ADHERENCE OF SONICATED ALBUMIN MICROBUBBLES DURING CARDIOPLEGIC ARREST AND AFTER BLOOD REPERFUSION: EXPERIMENTAL AND CLINICAL OBSERVATIONS WITH MYOCARDIAL CONTRAST ECHOCARDIOGRAPHY J. Thorac. Cardiovasc. Surg., June 1, 1997; 113(6): 1100 - 1108. [Abstract] [Full Text]